{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:22:34Z","timestamp":1794007354552,"version":"4.8.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse midline glioma (DMG) remains one of the most aggressive and uniformly fatal brain tumors, with a median overall survival (OS) of only 11 months and no systemic therapy yet demonstrating a meaningful survival benefit. Primarily affecting children and young adults, DMG represents an area of profound unmet clinical need where families and oncologists have faced decades of therapeutic stagnation. The recent accelerated approval by the United States (US) Food and Drug Administration (FDA) of dordaviprone (ONC201, ModeysoTM) for patients with progressive H3 K27M\u2013altered DMG marks the first regulatory recognition of a systemic therapy for this devastating disease.<\/jats:p>\n                  <jats:p>The decision has generated both optimism and debate within the neuro-oncology community. For many, the approval symbolizes long-overdue progress and affirms that systemic agents can demonstrate activity in DMG. For others, it raises concerns over whether the current evidence base is sufficient to justify widespread clinical adoption. The accelerated approval pathways allow for earlier access to therapy for serious life-threatening conditions based on surrogate endpoints, such as durable objective response rates (ORRs), while mandating post-approval studies to confirm benefit. However, while approvals using data from single-arm trials can make promising therapies available to patients expeditiously, such exceptional approvals present challenges that must be carefully considered. In the case of dordaviprone, this mechanism was applied following an integrated analysis of early-phase studies (ONC006 (NCT02525692), ONC013 (NCT03295396), ONC014 (NCT03416530),1 ONC016 (NCT05392374), and ONC018 (NCT03134131))2 that demonstrated measurable radiographic and biological responses in a subset of patients.<\/jats:p>\n                  <jats:p>Here, we examine the scientific, clinical, and regulatory context of the dordaviprone approval through contrasting perspectives. We consider both the landmark nature of this decision and the potential risks of overinterpreting preliminary evidence, aiming to clarify what this approval means for current practice and for the future development of therapies in DMG and other brain tumors.<\/jats:p>","DOI":"10.1093\/neuonc\/noag117","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:46:27Z","timestamp":1779277587000},"page":"1829-1839","source":"Crossref","is-referenced-by-count":3,"title":["Point\/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-9849","authenticated-orcid":false,"given":"Mustafa","family":"Khasraw","sequence":"first","affiliation":[{"name":"Duke University Medical Center, School of Medicine, Duke University , Durham, North Carolina, (M.K., K.S.)","place":["USA"]},{"name":"The Robert Preston Tisch Brain Tumor Center, Duke Cancer Institute, Duke University Medical Center, School of Medicine, Duke University , Durham, North Carolina, (M.K.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-5370","authenticated-orcid":false,"given":"Matthew D","family":"Dun","sequence":"additional","affiliation":[{"name":"Cancer Signaling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine, and Wellbeing, University of Newcastle , Callaghan, New South Wales, (M.D.D.)","place":["Australia"]},{"name":"Precision Medicine Research Program, Hunter Medical Research Institute , New Lambton Heights, New South Wales, (M.D.D.)","place":["Australia"]},{"name":"School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, New South Wales, (M.D.D.)","place":["Australia"]},{"name":"Pediatric Stream, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing , Callaghan, New South Wales, (M.D.D.)","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-1225","authenticated-orcid":false,"given":"Isabel","family":"Arrillaga-Romany","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard University , Boston, Massachusetts, (I.A.-R.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-0436","authenticated-orcid":false,"given":"Roel G W","family":"Verhaak","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale University , New Haven, Connecticut, (R.G.W.V.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6539","authenticated-orcid":false,"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"The Hospital for Sick Children, University of Toronto , Toronto, Ontario, (E.B.)","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-383X","authenticated-orcid":false,"given":"Jordan R","family":"Hansford","sequence":"additional","affiliation":[{"name":"Michael Rice Centre for Hematology and Oncology, Women\u2019s and Children\u2019s Hospital, Adelaide University , Adelaide, (J.R.H.)","place":["Australia"]},{"name":"South Australia Health and Medical Research Institute, Adelaide University , Adelaide, (J.R.H.)","place":["Australia"]},{"name":"South Australia Immunogenomics Cancer Institute, Adelaide University , Adelaide, (J.R.H.)","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0419-5381","authenticated-orcid":false,"given":"Kirit","family":"Singh","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, School of Medicine, Duke University , Durham, North Carolina, (M.K., K.S.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-5150","authenticated-orcid":false,"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of California , San Francisco, California, (S.M.)","place":["USA"]},{"name":"Department of Neurology, University of California , San Francisco, California, (S.M.)","place":["USA"]},{"name":"Department of Pediatrics, University of California , San Francisco, California, (S.M.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-7615","authenticated-orcid":false,"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Michigan Medical School , Ann Arbor, Michigan, (C.K.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard University , Boston, Massachusetts, (P.Y.W.)","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026080501513646700_noag117-B1","doi-asserted-by":"publisher","first-page":"vdac143","DOI":"10.1093\/noajnl\/vdac143","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol Adv"},{"key":"2026080501513646700_noag117-B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neurooncol"},{"key":"2026080501513646700_noag117-B3","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.1038\/s41467-019-12928-6","article-title":"A Bayesian machine learning approach for drug target identification using diverse data types","volume":"10","author":"Madhukar","year":"2019","journal-title":"Nat Commun"},{"key":"2026080501513646700_noag117-B4","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab169","article-title":"Pre-clinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neuro Oncol Adv"},{"key":"2026080501513646700_noag117-B5","doi-asserted-by":"publisher","first-page":"15977","DOI":"10.1074\/jbc.RA118.003719","article-title":"Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2","volume":"293","author":"Tegowski","year":"2018","journal-title":"J Biol Chem"},{"key":"2026080501513646700_noag117-B6","doi-asserted-by":"publisher","first-page":"171ra17","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026080501513646700_noag117-B7","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat Genet"},{"key":"2026080501513646700_noag117-B8","doi-asserted-by":"publisher","first-page":"83:2421-2437","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"key":"2026080501513646700_noag117-B9","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1093\/neuonc\/noad144","article-title":"A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered","volume":"26","author":"Jackson","year":"2024","journal-title":"Neuro Oncol."},{"key":"2026080501513646700_noag117-B10","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1093\/neuonc\/noac041","article-title":"Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas","volume":"24","author":"Przystal","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026080501513646700_noag117-B11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","article-title":"The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies","volume":"24","author":"Persson","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026080501513646700_noag117-B12","doi-asserted-by":"publisher","first-page":"102078","DOI":"10.1016\/j.cbpa.2021.07.003","article-title":"Substrates and interactors of the ClpP protease in the mitochondria","volume":"66","author":"Mabanglo","year":"2022","journal-title":"Curr Opin Chem Biol"},{"key":"2026080501513646700_noag117-B13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality","volume":"35","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"key":"2026080501513646700_noag117-B14","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-Mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"key":"2026080501513646700_noag117-B15","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1093\/neuonc\/noae001","article-title":"Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma","volume":"26","author":"Odia","year":"2024","journal-title":"Neuro Oncol."},{"key":"2026080501513646700_noag117-B16","doi-asserted-by":"publisher","first-page":"e00993","DOI":"10.1002\/prp2.993","article-title":"Characterization of TR-107, a novel chemical activator of the human mitochondrial protease ClpP","volume":"10","author":"Fennell","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"2026080501513646700_noag117-B17","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J Neurosurg Pediatr"},{"key":"2026080501513646700_noag117-B18","doi-asserted-by":"publisher","first-page":"115165","DOI":"10.1016\/j.ejca.2024.115165","article-title":"Real life data of ONC201 (dordaviprone) in pediatric and adult H3K27-altered recurrent diffuse midline glioma: results of an international academia-driven compassionate use program","volume":"216","author":"Di Carlo","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026080501513646700_noag117-B19","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.1093\/neuonc\/noae021","article-title":"Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort","volume":"26","author":"Odia","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026080501513646700_noag117-B20","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (dordaviprone) in recurrent H3 K27M-Mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026080501513646700_noag117-B21","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/neuonc\/noac030","article-title":"Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma","volume":"24","author":"Cantor","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026080501513646700_noag117-B22","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol."},{"key":"2026080501513646700_noag117-B23","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026080501513646700_noag117-B24","doi-asserted-by":"publisher","first-page":"926196","DOI":"10.3389\/fonc.2022.926196","article-title":"Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma: a retrospective analysis of the SIOP-E-HGG\/DIPG project","volume":"12","author":"Chavaz","year":"2022","journal-title":"Front Oncol"},{"key":"2026080501513646700_noag117-B25","doi-asserted-by":"publisher","first-page":"100183","DOI":"10.1016\/j.ejcped.2024.100183","article-title":"Re-irradiation for progressive diffuse intrinsic pontine glioma (DIPG): the Spanish experience","volume":"4","author":"Panizo-Morgado","year":"2024","journal-title":"EJC Paediatr Oncol"},{"key":"2026080501513646700_noag117-B26","doi-asserted-by":"publisher","first-page":"110865","DOI":"10.1016\/j.radonc.2025.110865","article-title":"Re-irradiation for children with diffuse intrinsic pontine glioma and diffuse midline glioma","volume":"207","author":"Shariff","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026080501513646700_noag117-B27","doi-asserted-by":"publisher","first-page":"e0249647","DOI":"10.1371\/journal.pone.0249647","article-title":"Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures","volume":"16","author":"Banan","year":"2021","journal-title":"PLoS One"},{"key":"2026080501513646700_noag117-B28","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults","volume":"41","author":"Wen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026080501513646700_noag117-B29","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1200\/JCO.24.00709","article-title":"Comments and controversies in oncology: the tribulations of trials developing ONC201","volume":"42","author":"Hansford","year":"2024","journal-title":"J Clin Oncol"},{"issue":":","key":"2026080501513646700_noag117-B30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(23)00070-037052964","article-title":"Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?","volume":"24","author":"Andr\u00e9","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026080501513646700_noag117-B31","doi-asserted-by":"publisher","first-page":"115230","DOI":"10.1016\/S1470-2045(23)00070-0","article-title":"Paediatric strategy forum for medicinalproduct development in Diffuse midline gliomas in children and adolescents Accelerate in collaboration with the European Medicines Agency withparticipation of the Food and Drug Administration","volume":"217","author":"Pearson","year":"2025","journal-title":"Eur J Cancer"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag117\/68370895\/noag117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/1829\/68370895\/noag117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/8\/1829\/68370895\/noag117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:51:45Z","timestamp":1785909105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/8\/1829\/8690955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,5,22]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag117","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,22]]}}}